Form 4: Ourania Tatsis, Verve Therapeutics Director, Reports Stock Option Grant

Director Ourania Tatsis reports the acquisition of stock options in Verve Therapeutics, Inc.

Summary

• Ourania Tatsis, a director of Verve Therapeutics, Inc., filed a Form 4 on June 28, 2024, reporting a transaction.
• The transaction involved the acquisition of a stock option to purchase 267,541 shares of Verve Therapeutics common stock at an exercise price of $5.02 per share on June 26, 2024.
• The stock option was granted under the company's 2021 Stock Incentive Plan as part of the director compensation program.
• The options vest in equal monthly installments through June 26, 2027, contingent upon continued service as a director.

Sentiment

Score: 7

Explanation: The document reflects a standard director compensation practice, indicating stability and alignment of interests. It is a neutral to slightly positive event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The director's continued service is tied to the vesting of the stock options, suggesting ongoing involvement with Verve Therapeutics.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing Verve Therapeutics' director compensation to peers like CRISPR Therapeutics, Editas Medicine, or Intellia Therapeutics would provide a benchmark for assessing the competitiveness of the package.
• Typical vesting schedules for director stock options range from three to four years, aligning with the vesting schedule reported in the document.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates